Home › Acute Myeloid Leukemia › North Carolina › Winston-Salem
Acute Myeloid Leukemia clinical trials in Winston-Salem, NC
18 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Winston-Salem (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
- Wake Forest University Health Sciences, Winston-Salem
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Novant Health Winston Salem, Winston-Salem
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Wake Forest University Health Sciences, Winston-Salem
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Wake Forest University Health Sciences, Winston-Salem
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Wake Forest University Health Sciences, Winston-Salem
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Wake Forest University Health Sciences, Winston-Salem
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
RecruitingPhase 2
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Wake Forest University Health Sciences, Winston-Salem
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
RecruitingPhase 1
- Wake Forest University Health Sciences, Winston-Salem
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
RecruitingObservational study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Recruiting
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
RecruitingPhase 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Recruiting
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RecruitingObservational study
- Wake Forest Baptist Health, Winston-Salem
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
RecruitingPhase 1/2
- Novant Health Cancer Institute, Winston-Salem
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Winston-Salem
- Cancer (all types)19 studies
- Multiple Myeloma14 studies
- Breast Cancer14 studies
- Cardiovascular Disease14 studies
- Non-Small Cell Lung Cancer12 studies
- COPD10 studies
- Ovarian Cancer10 studies
- Type 2 Diabetes9 studies
- Myelodysplastic Syndromes9 studies
- Glioblastoma8 studies
- Chronic Lymphocytic Leukemia8 studies
- Lung Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.